>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
联合应用奥利司他对比单用口服避孕药对多囊卵巢综合征患者疗效的Meta分析
作者:孔静庭1  王丽平2  于红2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属中大医院 妇产科, 江苏 南京 210009
关键词:奥利司他 多囊卵巢综合征 口服避孕药疗法 Meta分析 
分类号:R711.75
出版年·卷·期(页码):2021·40·第五期(690-697)
摘要:

目的:评价多囊卵巢综合征(PCOS)患者联合应用奥利司他对比常规口服避孕药疗法(OCT)对代谢及内分泌的影响。方法:检索PubMed、Web of Science、Cochrane Database of Systematic Reviews、Embase、CNKI及Wanfang数据库,检索时间从建库截至2020年11月,收集有关奥利司他对比OCT对PCOS患者代谢及内分泌影响的研究,按照纳入排除标准选择文献提取资料、评价质量、交叉核对并进行方法学质量评估,采用Stata 12.0统计软件进行Meta分析。结果:纳入6篇文献,共547例患者。5个主要结局指标中,口服避孕药联合应用奥利司他组与单用口服避孕药组治疗前后睾酮(T)水平变化的差异有统计学意义(SMD=-0.64,95% CI为-1.18~0.10,P=0.021)。10个次要结局指标中,甘油三酯(TG)水平变化的差异有统计学意义(SMD=-0.40,95% CI为-0.068~0.12,P=0.005);高密度脂蛋白胆固醇(HDL-C)水平变化的差异也有统计学意义(SMD=0.62,95% CI为0.32~0.92,P<0.001;但与体质量相关指标变化差异均没有统计学意义(P<0.05)。结论:联合应用奥利司他对比单用OCT治疗多囊卵巢综合征患者在调控T、TG及HDL-C水平方面疗效更佳。

Objective: To evaluate the effect of orlistat combined with conventional oral contraceptive therapy (OCT) on metabolism and endocrine in patients with polycystic ovary syndrome (PCOS). Methods: We searched PubMed, Web of Science, Cochrane Database of Systematic Reviews,Embase, CNKI and Wanfang databases for trials that assessed orlistat in PCOS patients with OCT from establishment of the database to November 2020. The reviewers selected literature, extracted data and evaluated quality independently, cross-checked, and evaluated the quality of methodological according the inclusion and exclusion criteria. Stata 12.0 software was used for the Mete-analysis. Results: A total of 6 studies involving 547 patients were included. The main endpoint of the study:Among the 5 main outcome indicators, the difference in testosterone (T) levels before and after treatment in the oral contraceptive in combination with orlistat group and the oral contraceptive group was statistically significant[SMD=-0.64, 95% CI (-1.18,-0.10), P=0.021]; among the 10 secondary outcome indicators, the difference in triglyceride (TG) level changes was statistically significant[SMD=-0.40, 95% CI (-0.068,-0.12), P=0.005]. The difference in high-density lipoprotein cholesterol (HDL-C) levels was statistically significant[SMD=0.62, 95% CI (0.32, 0.92), P<0.001]. While orlistat was known as a weight loss drug, compared with single oral contraceptives, before and after combined oral contraceptive treatment, the changes in weight-related indicators were not statistically significant. Conclusion: Comparing with OCT alone, the combination of orlistat and OCT may be of some auxiliary significance in the regulation of testosterone, triglyceride, and high-density lipoprotein-cholesterol levels in PCOS patients.

参考文献:

[1] PATEL S.Polycystic ovary syndrome(PCOS),an inflammatory,systemic,lifestyle endocrinopathy[J].J Steroid Biochem Mol Biol,2018,182:27-36.
[2] VATOPOULOU A,TZIOMALOS K.Management of obesity in adolescents with polycystic ovary syndrome[J].Expert Opinion on Pharmacotherapy,2020,21(2):207-211.
[3] IGNATOV A,ORTMANN O.Endocrine risk factors of endometrial cancer:polycystic ovary syndrome, oral contraceptives,infertility,tamoxifen[J].Cancers,2020,12(7):1766.
[4] BALDANI D P,SKRGATIC L,OUGOUAG R,et al.The cardiometabolic effect of current management of polycystic ovary syndrome:strategies of prevention and treatment[J].Gynecol Endocrinol,2018,34(2):87-91.
[5] PAPADAKIS G,KANDARAKI E,PAPALOU O,et al.Is cardiovascular risk in women with PCOS a real risk? Current insights[J].Minerva Endocrinologica,2017,42(4):340-355.
[6] DOKRAS A,PLAYFORD M,KRIS-ETHERTON P M,et al.Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome[J].Clin Endocrinol,2017,86(5):739-746.
[7] AMIRI M,RAMEZANI-TEHRANI F,NAHIDI F,et al.Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome:a meta-analysis comparing products containing cyproterone acetate with third generation progestins[J].Metabolism,2017,73:22-35.
[8] VOSNAKIS C,GEORGOPOULOS N A,ROUSSO D,et al.Diet, physical exercise and Orlistat administration increase serum anti-Mullerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS)[J].Gynecol Endocrinol,2013,29(3):242-245.
[9] PANIDIS D,TZIOMALOS K,PAPADAKIS E,et al.The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome[J].Clin Endocrinol,2014,80(3):432-438.
[10] WANG F F,WU Y,ZHU Y H,et al.Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome:a systematic review and network meta-analysis[J].Obes Rev,2018,19(10):1424-1445.
[11] LEGRO R S,DODSON W C,KRIS-ETHERTON P M,et al.Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome[J]. Clin Endocrinol Metab,2015,100(11):4048-4058.
[12] SONG J H,RUAN X Y,GU M Q,et al.Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance[J].Gynecol Endocrinol,2018,34(5):413-417.
[13] 周海悦,胡燕,薛晓玲.奥利司他治疗肥胖型多囊卵巢综合征不孕患者的疗效观察[J].河北医药,2018,40(17):2598-2602.
[14] 李明群.炔雌醇环丙孕酮片联合奥利司他治疗肥胖型多囊卵巢综合征不孕患者的效果观察[J].中国妇幼保健,2019,34(21):5005-5008.
[15] 闵敏,阮祥燕,赵越,等.奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J].首都医科大学学报,2019,40(4):572-577.
[16] 陈东娜.奥利司他胶囊联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的效果[J].河南医学研究,2019,28(12):2215-2217.
[17] GRAFF S K,MARIO F M,ZIEGELMANN P,et al.Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS:systematic review and meta-analysis[J].Int J Clin Pract,2016,70(6):450-461.
[18] SALEEM F,RIZVI S W.New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome[J].Cureus,2017,9(11):e1844.
[19] ESMAEILINEZHAD Z,BARATI-BOLDAJI R,BRETT N R,et al.The effect of synbiotics pomegranate juice on cardiovascular risk factors in PCOS patients:a randomized,triple-blinded,controlled trial[J].Endocrinol Invest,2020,43(4):539-548.
[20] ORIO F,MUSCOGIURI G,GIALLAURIA F,et al.Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome:a randomized controlled trial[J].Clin Endocrinol,2016,85(5):764-771.
[21] THANNICKAL A,BRUTOCAO C,ALSAWAS M,et al.Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS):a systematic review and meta-analysis[J].Clin Endocrinol,2020,92(4):338-349.
[22] ERDMANN J,LIPPL F,KLOSE G,et al.Cholesterol lowering effect of dietary weight loss and orlistat treatment-efficacy and limitations[J].Aliment Pharmacol Ther,2004,19(11):1173-1179.
[23] INSFRAN L M,CAMPOS P C,ROMERO P R,et al.Liver transplantation due to fulminant liver failure secondary to acute submassive necrosis in a patient treated with orlistat[J].Transplantation,2018,102:S881-S882.
[24] MARTINEZ-INSFRAN L A,ALCONCHEL-GAGO F,PARRILLA-PARICIO P.Fulminant liver failure secondary to submassive hepatic necrosis in a patient treated with Orlistat.A case report[J].Revista Espanola De Enfermedades Digestivas,2019,111(1):86.
[25] VAN AERTS R M M,BERNTS L H P,GEVERS T J G,et al.Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients[J].Clin Pharmacol Ther,2019,106(6):1338-1345.
[26] EL HAGGAR S M,MOSTAFA T M.Cardiovascular risk in Egyptian healthy consumers of different types of combined oral contraceptives pills:a comparative study[J].Endocrine,2015,49(3):820-827.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 343110 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364